Trinity Biotech signs Lucid ATM deal for up to US$4.35 million ADS offering
PUBT · 06/12 20:32
Share
Listen to the news
- Trinity Biotech entered an at-the-market offering agreement with Lucid Capital Markets to sell up to USD 4.35 million of ADSs.
- Each ADS represents 20 A ordinary shares; Lucid will act as sales agent using commercially reasonable efforts.
- Lucid will receive a 3% commission on the gross sales price of ADSs sold under the program.
- The company terminated its prior at-the-market offering agreement with Craig-Hallum; the program had been inactive since March 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-001322), on June 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved